Identification and understanding of precautionary legends in the Mexican warning labeling for sweetened beverages.

Salud Publica Mex

Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico..

Published: February 2025

Objective: To evaluate the identification and objective understanding of precautionary legends regarding non-sugar sweeteners (NSS) and caffeine in sweetened beverages (SBs).

Materials And Methods: The labeling questionnaire from the National Health and Nutrition Survey 2021 was administered to Mexican adults over 20 years old. Identification was assessed when the participants reported seeing the legend. Objective understanding was determined by correctly evaluating the nutritional quality of SBs. For this evaluation, 50% of the participants were presented with an image of a sugary drink displaying the precautionary legend, while the other 50% without the legend.

Results: For the NSS legend, the odds of correctly evaluating the nutritional quality of a SB were higher among participants who identified the NSS legend (OR: 1.62, 95%CI: 1.12,2.34) compared to those who did not. Similarly, the odds were higher when the product was presented with the legend compared to when it was not (OR: 1.23, 95%CI: 1.01,1.51). For the caffeine legend, the odds of correctly evaluating the nutritional quality of a SB were four times higher among participants who identified the legend compared to those who did not (OR: 3.97, 95%CI: 1.98,7.97).

Conclusion: Greater effectiveness was observed among participants who identified the legends. We recommend implementing strategies to enhance the identification of precautionary legends.

Download full-text PDF

Source
http://dx.doi.org/10.21149/15879DOI Listing

Publication Analysis

Top Keywords

precautionary legends
12
correctly evaluating
12
evaluating nutritional
12
nutritional quality
12
participants identified
12
understanding precautionary
8
sweetened beverages
8
objective understanding
8
nss legend
8
legend odds
8

Similar Publications

Identification and understanding of precautionary legends in the Mexican warning labeling for sweetened beverages.

Salud Publica Mex

February 2025

Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico..

Objective: To evaluate the identification and objective understanding of precautionary legends regarding non-sugar sweeteners (NSS) and caffeine in sweetened beverages (SBs).

Materials And Methods: The labeling questionnaire from the National Health and Nutrition Survey 2021 was administered to Mexican adults over 20 years old. Identification was assessed when the participants reported seeing the legend.

View Article and Find Full Text PDF

Targeted drug delivery to SARS-CoV-2 host target proteins for preventing or blocking COVID-19 infection is making serious concern during COVID-19 pandemic and its consequent waves around the globe. People seek reliable, effective folkloric preventive medication for immediate and precautionary relief from COVID-19. These folkloric medicines were effective and saved many patients during the past COVID-19 pandemic.

View Article and Find Full Text PDF

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.

J Med Case Rep

February 2021

Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Pl, Box 1185, New York, NY, 10029, USA.

Background: Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. As a precautionary measure, many clinical studies halted enrollment during the initial surge of the global Novel Coronavirus Disease (COVID-19) pandemic. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!